Atrial Fibrillation Ablation Fails to Outperform Sham on Quality of Life
TL;DR Summary
The PVI-SHAM-AF trial presented at ESC 2026 found that ablation reduced AF episodes and burden versus sham, but six-month quality-of-life gains (AFEQT) were not significantly better with ablation, indicating a strong placebo/cardioversion effect and prompting calls for further research before broad adoption of AF ablation.
Topics:business#ablation#atrial-fibrillation#health#placebo-controlled-trial#pvi-sham-af#quality-of-life
Reading Insights
Total Reads
0
Unique Readers
7
Time Saved
5 min
vs 6 min read
Condensed
96%
1,034 → 45 words
Want the full story? Read the original article
Read on Medscape